Claim Ledger
33% answered
Did management answer the analysts?
12 analyst questions audited, 6 evaded or deflected.
View Claim Ledger →Cipla Ltd — Q1 FY26
Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY).
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY). India business crossed INR 3,000 crore for the first time in a Q1, growing 6% YoY, but branded prescription growth was muted due to slow respiratory/acute market (4-5% growth) and sales force realignment. US revenue was $226 million, impacted by price erosion in a large product, but new launches (NanoPaclitaxel, Nilotinib) and Lanreotide recovery provide cushion. Management maintained FY26 EBITDA margin guidance of 23.5%-24.5%. Key risks include Revlimid revenue phasing uncertainty and slower India branded growth recovery.
सिप्ला ने पहली तिमाही (अप्रैल-जून 2025) में 6,957 करोड़ रुपये की कमाई की, जो पिछले साल से 4% ज्यादा है। कंपनी का मुनाफा (PAT) 1,298 करोड़ रुपये रहा, जो 10.2% बढ़ा। भारत में पहली बार किसी पहली तिमाही में बिक्री 3,000 करोड़ रुपये पार हुई, लेकिन डॉक्टरों के प्रिस्क्रिप्शन वाली दवाओं की बिक्री धीमी रही, क्योंकि सर्दी-खांसी जैसी बीमारियों का बाजार कमजोर था और सेल्स टीम में बदलाव हुआ। अमेरिका में कमाई 226 मिलियन डॉलर रही, जहां एक बड़ी दवा की कीमत गिर गई, लेकिन नई दवाओं (जैसे नैनोपैक्लिटैक्सेल, निलोटिनिब) और लैनरियोटाइड की बिक्री से राहत मिली। कंपनी ने पूरे साल 23.5%-24.5% मुनाफा मार्जिन का अनुमान बनाए रखा है। जोखिम: रेवलिमिड दवा की कमाई अनिश्चित है और भारत में ब्रांडेड दवाओं की बिक्री धीमी रह सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Revlimid revenue phasing uncertainty
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue
$226M
Flat vs prior quarter
US revenue sustained despite price erosion in a large product; new launches partially offset.
India Business Revenue
INR 3,000 Cr
+6% YoY
First time crossing INR 3,000 crore in Q1; now 44% of global revenue.
Albuterol MDI Market Share
19.5%
Recovered from prior lows
Ranked #1 in US Albuterol MDI market; over 50 million inhalers supplied since launch.
Gross Margin
68.8%
+156 bps YoY
Expansion driven by favorable product mix and portfolio management.
What Changed vs Last Quarter
NEW
US revenue target of ~$1 billion by FY27
CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
NEW
India branded business to grow in line with IPM in next three quarters
COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
UPDATED
FY26 EBITDA margin guidance maintained at 23.5%-24.5%
Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments.
UPDATED
Biosimilar launch in US expected in Q2 FY26
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
DROPPED
Two to three peptide launches in FY26
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
DROPPED
U.S. revenue run rate of ~$220 million for Q1 FY26
Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
NEW RISK
Revlimid revenue phasing uncertainty
Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
NEW RISK
Slower India branded prescription growth
India branded business grew only ~3% (ex-consumer), impacted by slow respiratory/acute market and sales force realignment; recovery may take longer.
NEW RISK
Indore facility reinspection risk
Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
NEW RISK
GLP-1 market competition and execution
Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
RISK GONE
Generic Revlimid exclusivity loss
Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
RISK GONE
Lanreotide supply normalization uncertainty
While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
RISK GONE
U.S. tariff and regulatory risks
Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
RISK GONE
Execution risk on peptide and respiratory pipeline
Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q3 FY25, Q4 FY25
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Mentioned in Q1 FY25, Q2 FY25
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY25, Q2 FY25
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Mentioned in Q2 FY25, Q3 FY25
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
Mentioned in Q1 FY25, Q4 FY25
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
Fast read
Guidance and risk preview
Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D...
Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
View Risks →